Aquaporin 2 Polyclonal Antibodies
Myosin-Based Protein-Protein Interaction Assay
HIV-1 Clone Bal.01
Resurfaced Stabilized Core 3 (RSC3) Protein, Derived Proteins, and DNA Encoding These Proteins: RSC3, RSC3 delta371I, RSC3 delta371I/P363N, RSC3 G367R
- RSC3 (Catalog# 12042): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=214
- RSC3 delta371I (Catalog# 12043): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=146
- RSC3 delta371I/P363N (Catalog# 12362):
A VSV-EBOV-Based Vaccine Against COVID-19
Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)
A Neural Stem Line from a Niemann Pick C (NPC) Type 1 Patient for Therapy Development
This technology includes a neural stem cell (NSC) line derived from a Niemann Pick C (NPC) patient, aimed at advancing research and drug development for NPC, an inherited neurodegenerative disorder characterized by the accumulation of cholesterol in neurons. The NSCs, which serve as a crucial intermediate cell type, can be differentiated into any neuronal or glial cell of the brain or spinal cord under appropriate culture conditions. These cells originate from fibroblasts reprogrammed into induced pluripotent stem cells.
Neural Stem Cells from an iPSC Line Ubiquitously Expressing Green Fluorescent Protein for Basic Science Research and Cell Line Tracking
This technology involves neural stem cells (NSCs) derived from pluripotent stem cells (PSCs) that can differentiate into neurons and glia. The key feature of this technology is the CY2 EEF1A1 GFP iPSC line, which includes a green fluorescent protein (GFP) expressed under the EEF1A1 promoter, leading to its ubiquitous expression in cells. This characteristic makes the NSCs and the neural cells differentiated from this line exhibit green fluorescence. Such cells, when transplanted into animal models like mice and rats, can be easily tracked due to their fluorescence.
Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties
One of the most challenging hurdles in creating safe and effective new medicines for many diseases is finding drugs that are effective without causing off-target cardiac issues, such as cardiac arrythmias. In collaboration with NIDA, scientists at NCATS have developed a series of novel and highly specific dopamine D3 receptor agonists and antagonists that have potential to target and treat Parkinson’s disease, Schizophrenia, Depression, and substance-use disorders including opioid addiction.